LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Kodu・Aktsiate loetelu・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

4.77 -0.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.61

Max

4.9

Põhinäitajad
By Trading Economics
Sissetulek	9.6M -162M
Müük	-14M 5.2M
Aktsiakasum	-0.36
Kasumimarginaal	-3,135.324
Töötajad	800
EBITDA	6.4M -141M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+38.38% upside

Turustatistika
By TradingEconomics
Turukapital	138M 2.5B
Eelmine avamishind	5.19
Eelmine sulgemishind	4.77

Uudiste sentiment

By Acuity

50%

166 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

4.15 / 4.75 Toetus ja vastupanu

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. dets 2025, 22:13 UTC

Tulu

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9. dets 2025, 21:40 UTC

Tulu

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9. dets 2025, 18:51 UTC

Omandamised, ülevõtmised, äriostud

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9. dets 2025, 16:57 UTC

Suurimad hinnamuutused turgudel

Clear Secure Rises on Medicare Identity Verification Contract

9. dets 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9. dets 2025, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings Stake in Lenovo Now at 32.34%

9. dets 2025, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9. dets 2025, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9. dets 2025, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9. dets 2025, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9. dets 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9. dets 2025, 22:42 UTC

Tulu

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9. dets 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. dets 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9. dets 2025, 21:36 UTC

Tulu

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9. dets 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9. dets 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9. dets 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Teck Reports Voting Results From Special Meeting of Hldrs

9. dets 2025, 20:26 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9. dets 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9. dets 2025, 19:52 UTC

Tulu

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9. dets 2025, 19:17 UTC

Tulu

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. dets 2025, 17:11 UTC

Tulu

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

38.38% tõus

12 kuu keskmine prognoos

Keskmine 6.67 USD 38.38%

Kõrge 8 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Recursion Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

166 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.